Market revenue in 2023 | USD 2,278.4 million |
Market revenue in 2030 | USD 5,273.3 million |
Growth rate | 12.7% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 35.95% in 2023. Horizon Databook has segmented the Europe immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
High standard of living, consumer awareness about early diagnosis, and presence of a well-established healthcare system act as key drivers for market growth. High disposable income, technological advancements, and the geographic presence of key manufacturers are driving the market.
Development of advanced diagnostics products or devices with improved accuracy, sensitivity, and precision requires intensive seed capital. Thus, financial burden may restrain the market. High cost of diagnostic tests for neurological disorders may impede the market growth.
The geographic presence of important regulatory bodies, such as the European Medicines Agency (EMA), which plans for the development of a unique program focusing on formulating multiple approaches in novel immunoassay kits for the identification of neurological biomarkers, provides strong commercial opportunities for new entrants in this market.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe immunoassay for neurological biomarkers market , including forecasts for subscribers. This continent databook contains high-level insights into Europe immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account